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ABSTRACT 
In this study, polymer-based microparticles are used to improve the therapeutic properties of ceftriaxone (CEF) and 
render them safer. Poly-3-hydroxybutyrate (P3HB) and poly-3-hydroxybutyrate/polyethylene glycol (P3HB-PEG)-
based microparticles were prepared by two methods: a double emulsification technique and spray-drying. The 
microparticles were characterized in terms of size and zeta potential, morphology, total drug loading and drug 
release. The microparticles had spherical shapes with diameters of a size range from 0.74 to 1.55 m (emulsification 
technique) and from 3.84 to 6.51 m (spray-drying); CEF encapsulation efficiency was around 63% and 49% for 
these methods respectively. The CEF release from microparticles obtained by spray-drying reached 100% after 
150h, while for microparticles obtained by emulsification technique the total release of CEF did not exceed 34% 
after 312 h. The release profiles could be best explained by Zero order kinetics model, Higuchi and Korsmeyer-
Peppas models, as the plots showed high linearity. Antibacterial activity of the microparticles was evaluated against 
gram-positive and gram-negative bacterial strains. In general, CEF encapsulation in polymeric microparticles 
preserves the therapeutic efficacy of the CEF and provides its prolonged effect. 
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INTRODUCTION 
Scientific research and development of innovative drug delivery systems is a rapidly developing area 
worldwide. This trend is going to be strengthened in the future, as the cost of health care requires reducing costs and 
improving the effectiveness of existing dosage forms. Currently, we observe the crisis of antibiotic therapy not only 
due to a large number of resistant microorganisms, but also due to the lack of drugs that do not have resistance of 
one or other pathogens. Moreover, bacteria appeared that are resistant to all existing antibiotics. In the past, the 
pharmaceutical industry solved the problem of resistance by producing a new, more effective antibiotic. However, 
today there are no fundamentally new classes of antibiotics that are acceptable for clinical use and the development 
of new drugs usually takes about 10-15 years.
1 
Therefore, the interest of the pharmaceutical sciences is gradually 
shifting from the discovery of new chemicals to the optimization of their routes of administration and delivery. 
Thus, one of the drawbacks of classical antimicrobial therapy is that many intracellular bacteria are at rest 
or still, deactivating, and dramatically changing the permeability of cell membranes, which affects the sensitivity to 
antibacterial agents. Therefore, such bacteria can persist for a long time.
2 
In addition, the most severe complications 
of antibiotic therapy are anaphylactic shock, allergic reactions, neurotoxic phenomena, dysbiosis, and liver damage.
3 
The use of antibacterial drugs in large doses to inhibit the vital activity of microorganisms and overcome resistance 
also leads to delayed and late serious depression of immunological system, which leads to the development of 
systemic diseases including the formation of malignant tumors. 
To overcome these problems various approaches are developed including the use of immobilized 
biologically active agents, such as fullerenes, carbon nanotubes, graphite, nanodiamonds, graphene oxide, metal 
oxides' nanoparticles, and metalloids, which may be used for bacterial infections treatment.
4,5 
The mechanism by 
which nanostructured materials inactivate bacteria is complex and depends on intrinsic properties materials, for 
example, composition and surface modification, the nature of the target microorganisms, and the characteristics of 
the environment in which cell-materials interactions take place.
6
 
Another popular approach to increase the effectiveness of antibiotic therapy is the use of antibacterial drugs 
in the form of microcarriers and nanocarriers.
7-10
 By placing antibiotics in carriers we can expect improved deliver)' 
to infected cells, increased bioavailability of drugs with poor absorption characteristics, prolonged drug residence 
time, targeted transport of therapeutic agents to specific organs, reduced toxicity and stability.
11-13
 A significant 
portion of antibiotics during the first 6-8 h is mostly removed from the body. The use of microparticles allows 
extending the elimination time.
12,14
 
Ceftriaxone (CEF) is a cephalosporin antibiotic of third generation that is effective mostly against gram-
positive and gram-negative bacteria. CEF is reportedly hygroscopic, sensitive to humidity, heat and light, and 
oxidizing agents; CEF aqueous solution is reportedly unstable. In solution, the optimal pH for CEF stability is 7.5 
giving more than 6h without significant degradation at 37 °C, however degradation is faster at lower or higher pH.15 
CEF is poorly absorbed through mucosal membranes,
16-18
 which indicates that in this pharmaceutical form it is 
intended only for intravenous, intramuscular or subcutaneous injections, and this limits its therapeutic use in other 
modes of administration.
19
 
The use of the encapsulated form of CEF in the form of microcarriers and nanocarriers will increase the 
stability and bioavailability of the drug, provide a reduction in undesirable systemic effects and also allow for oral, 
nasal, and inhalative administration into the body.
20-22 
The literature describes examples of delivery systems for cephalosporin based on various materials. Thus, 
Kumar et al.
23
 demonstrated the efficacy of CEF-loaded solid lipid nanoparticles for gram-positive and gram-
negative bacterial strains. In another article, the authors noted the pronounced antibacterial effect of conjugates of 
silver nanoparticles with CEF in the culture of various pathogenic strains of bacteria.
24
 In addition, examples of 
prolonged forms of CEF in the form of conjugates based on poly(styrene-alt-maleic)anhydride,
25
 PEGylated 
microscopic lipospheres,
21
 and chitosan nanoparticles
26 
are given. 
Among the huge variety of polymers, used to produce microparticles and nanoparticles for drug delivery, 
polyhydroxyalkanoales (PHA) are widely used in controlled release applications, including the encapsulation of 
different antimicrobial drugs.
27-34
 This class of polyester attracts attention due to the presence of unique properties – 
natural origin, true biodegradation and biocompatibility. PHAs are thermoplastic, have less effect on pH values of 
tissues and have a longer in vivo degradation period, which allows them to be used for the development of 
prolonged drug delivery systems. Varying the conditions for PHA synthesis, as well as the production of composite 
and block copolymer materials with hydrophilic components makes it possible to design microcarriers and 
nanocarriers suitable for drug delivery systems.
35-37
 
The key role in the formation of micro- and nanoparticles is played by the choice of their production 
technique. Currently, such carriers can be prepared using a variety of methods: electrohydrodynamic techniques,
38-41
 
microfluidic method,
42,43
 coacervation
44-45
; polymerization of monomers,
46
 emulsification of solutions (two- and 
three-component emulsions with evaporation or diffusion of the solvent);
47-49
 spray drying of solutions
50-52
 etc. With 
regard to the preparation of PHA-based microparticles and nanoparticles, the emulsion method is the most adapted 
from those, listed above and recently the application of the spray drying method has become topical. 
It should be noted that spray drying is a popular way of depositing drugs in various polymer carriers, but 
with respect to PHAs this method has not been properly developed. Single examples of the use of spray drying for 
producing microparticles based on polyhydroxybutyrate (P3HB) loaded with analgesic drug – paracetamol.53 
However, publications on the preparation of PHA-based antibiotic-loaded microparticles by spray drying method 
have rarely been seen until now. 
Earlier, we showed examples of the successful encapsulation of various antibacterial drugs in micro-
particles from P3HB and its copolymers with 3-hydroxyvalerate using the emulsion method.
29,54
 For the first time, 
the possibility of encapsulating an antitumor drug in a P3HB microparticle was demonstrated using the spray drying 
method.
55,56
 The dependency of microparticle characteristics (yield. average diameter, zeta potential) on the 
parameters of the production process (inlet temperature, polymer solution feed rate, and polymer solution 
concentration) has been established.
57
 
Thus, the main objective of our study was the development of a delivery system for CEF as polymer 
microparticles. Microparticles from P3HB and its blend with polyethylene glycol (PEG) were obtained by the spray-
drying technique and the emulsion method. Furthermore, we evaluated the effects of these methods and chemical 
composition on the properties of the microparticles and CEF release in vitro. Besides, microbiological evaluation of 
CEF-loaded РИА microparticles was also investigated in vitro. 
 
MATERIALS AND METHODS 
 
Materials 
P3HB with low molecular weight was produced at tl Institute of Biophysics of the Siberian Branch of the 
Russian Academy of Sciences (SB RAS) by the microbial fermentation process. The register mark of material is 
"Bioplastotan™." PEG 35,000 Da was purchased Sigma-Aldrich USA, CEF – Farm-Center (Russia). 
 
Preparation of microparticles by emulsion method 
Microparticles were prepared by the solvent evaporation technique using (oil/water) emulsions. The 
emulsion contained 0.1 g P3HB or P3HB/PEG (50:5 in 10 ml of dichloromethane and 100 ml 0.5% PVA. The 
obtained emulsions were mechanical stirred at 24000 rpm during 5min (IKA Ultra-Turrax T25 digital high-
performance homogenizer Germany). All emulsions were continuously mixed mechanically for 24h until the solvent 
complete evaporated. Microparticles were collected by centrifuging (at 10,000 rpm, for 5min), rinsed four times 
distilled water and lyophilic dryer in an Alpha 1-2 1 plus (Christ, Germany). 
The described above method was also used for loading CEF into microparticles. The CEF  was dissolved in 
1 ml of distillated water and added the solution of 0.1 g P3HB or P3HB/PEG (50:50) dichloromethane and the 
resulting emulsion was sonicated at 6W for 2min (Misonix 3000. USA). Then obtained emulsions were added to 
0.5% (w/v) PVA solution al stirring at 24.000 rpm (IKA Ultra-Turrax T25 digital high-performance homogenizer. 
Germany). Centrifugation and washing conditions were similar to those described earlier. 
 
Preparation of microparticles by spray-drying 
Spray-dried microparticles were prepared from P3HB or P3HB/PEG (50:50) solutions in dichloromethane 
(400 mg, 40 ml) using Buchi B-290 Spray dryer (BUCHI Laboratory Equipment, Switzerland, Elawil). In brief, a 
polymer solution was sprayed through a nozzle (diameter of 0.7 mm) at a feed rate 1.5ml/min at the inlet 
temperature 75°C. The value of the aspirator (current of argon) was supported at the maximum gas flow rate 35 
m
3
/h. 
CEF-loaded microparticles were prepared by spray drying of water/oil-emulsions. In this regard, an 
aqueous solution of GEE (80mg/ml) was added to the solution of the polymer and those emulsions were 
homogenized using sonication at a power of 6W for 2min The obtained homogeneous emulsions were continuously 
stirred (700rpm) and sprayed at the described above parameters. 
 
Characterization of microparticles 
Morphological analysis 
To study the morphology of microparticles surface, the scanning electron microscopy of samples was 
performed. S-5500 (Hitachi. Tokyo, Japan) in the Center of the common use, Krasnoyarsk Scientific Center, 
Siberian Branch of Russian Academy of Sciences. The samples were sputter-coated with platinum using an 
electrical potential of 2.0kV at 25 mA for 6min with a sputter coaler K550X (Emitech, Quorum Technologies Ltd., 
UK). 
Process yield (%) 
The processing yields were defined as the percentage of the weight of microparticles (Wm) compared to the 
weight of polymer (Wp) in the initial solution as shown in Equation (1): 
 (1) 
Measurement of the particle size and zeta potential 
About 5mg of each sample was suspended in bidistilled water and sonicated at 6W for 1 min. The size 
distribution and polydispersity index (PdI) of microparticles were determined by the first measuring of Brownian 
motion of particles using the dynamic light scattering method on the Zetasizer Nano ZS (Malvern, Worcestershire, 
UK). The average particle size measurements were studied in triplicates for all samples. The surface charge of 
microparticles was characterized by value of zeta potential, which was determined by the electrophoretic mobility of 
the particles in the suspensions. 
 
Drug encapsulation efficiency 
The amount of drug loaded in the polymeric microparticles was determined by spectrophotometric analysis. 
The CEF-loaded MPSD were dissolved in dichloromethane and water was then added in a ratio 1:1. The resulting 
emulsion was mechanically stirred on a shaker to extract the CEF into water. An aqueous phase containing CEF was 
taken and optical density 
measurements were made. CEF encapsulation efficiency of MPEM was measured according to the 
procedure described previously.
54
 
The quantity of CEF loaded into microparticles was determined on a UV-Vis spectrophotometer Cary 60 
(Agilent Technologies, Selangor, Malaysia) by measuring the UV-Vis absorbance at 240nm using pre-built 
calibration graphs. The experiment was carried out in triplicates. The encapsulation efficiency (EE) was defined as 
the percentage of the drug weight in microparticles (Wm) compared to the initial weight of drug (Wi) as shown in 
Equation (2): 
(2) 
 
In vitro CEF release studies 
The controlled drug release from CEF-loaded microparticles was carried out in vitro. The microparticles 
were initially sterilized by UV radiation for 40 min and placed in a sterile centrifuge tubes, containing 10 ml of 
phosphate-buffered saline (PBS, pH 7.4). Those centrifuge tubes were exposed to thermostat at 37 °C (n=3). 
Microparticles were precipitated by centrifugation (10,000 rpm, 10 min). One milliliter of supernatant was 
withdrawn from the centrifuge tube to observe the change in CEF concentration by UVVis spectroscopy (Agilent 
Technologies, Malaysia), and volume was replenished with fresh PBS, the dilution was taken into account in the 
calculations. The amount of CEF in the supernatant was determined at 240 nm. Triplicate measurements were 
performed for all samples. 
The data obtained from in vitro experiments were fitted to various mathematical models to assess the CEF 
release kinetics.
58
 
 
Zero-order kinetic model 
(1) 
where Qt is amount of drug dissolved in time t, Q0 is initial amount of drug in the solution, and K0 is zero-order 
release constant. 
 
First-order kinetic model 
(2) 
where Qt is amount of drug dissolved in time t, Q0 is initial amount of drug in the solution, and K1 is first-order 
release constant. 
 
Higuchi model 
The model relates cumulative drug release versus square root of time as shown in Equation (3). 
(3) 
 
Hixson–Crowell model 
This model relates cube root of drug percentage remaining in microparticles versus time. As given by 
Equation (4). 
(4) 
 
Korsmeyer–Peppas model  
This model relates exponentially the drug release to the elapsed time. The equation is given as Equation (5). 
(5) 
 
Microbiological efficiency evaluation 
The antibacterial activity of CEF-loaded microparticles was determined using the disc diffusion test for 
grampositive bacteria Staphylococcus aureus and gramnegative bacteria Escherichia coli. This test is based on the 
diffusion of an antibacterial drug from the carrier into a dense nutrient medium and inhibition of the growth zone of 
the culture.
59
 Susceptibility disk of CEF was used as the control (with a drug content of 0.03 mg, BioRad, France). 
The concentration of encapsulated CEF when microparticles were introduced into the cell culture as a suspension 
was 0.3 mg. The Mueller-Hinton medium (BioRad, France) was diluted in distilled water (25 ml per dish) and 
heated until completely dissolved. The nutrient medium was then sterilized by autoclaving at 1A and 121 °C for 15 
min. Petri dishes were filled with medium on a horizontal surface so that the thickness of the agar layer in the dish 
was on average 4 mm, and left at room temperature until completely solidified. 
To determine the sensitivity of the microorganisms, an inoculum corresponding to a density of 0.5 
according to the McFarland standard and containing about 1.5×108 CFU/ml was used. The inoculation was 
performed with sterile cotton swabs with uniform strokes in aseptic conditions. After 15 min, in the middle of the 
Petri dish, vertical wells of 15mm in diameter were made in agar and the microparticles suspensions in physiological 
saline in a volume of 100 l were dropped into them. The application of the disks was performed on agar without 
well formation using sterile tweezers. Upon completion, Petri dishes were left in a thermostat at 37C. After a day, 
the diameters of the culture growth retardation zones were measured. 
 
RESULTS AND DISCUSSION 
 
In this study, PHAs-based microparticles are used to improve the therapeutic properties of CEF and render 
antibiotic safer. Microparticles were prepared by two methods, with a double emulsification technique and with a 
spray-drying (abbreviations are presented in Table 1). 
 
Characterization of microparticles 
The size of microparticles and PdI were determined using dynamic light scattering by analyzer of Zetasizer 
Nano ZS. Results revealed that microparticles had a size range from 0.74 to 1.55 mm (emulsion method) and from 
3.84 to 6.51 mm (spray-dried method); a negative zeta potential ranging from –17.8 to –28.0mV and from –37.5 to –
95.7 mV, respectively (Table 2). It is advisable to assume that the observed difference in zeta-potentials is probably 
due to the adsorption on the surface of the microparticles of polyvinyl alcohol, which is used in the emulsion method 
and absent in the spray drying method. A similar effect was mentioned in the work of Francis et al.
60
 the nonionic 
surfactants such as PVA are known to strongly adhere on the microsphere surface by anchoring the hydrophobic tail 
into the polymer only when it is hydrophobic, leaving the polar head protruded on the surface. Thus, with an 
increase in the concentration of polyvinyl alcohol from 0.5% to 1%, the zeta potential of the P3HB microparticle 
decreased from –34mV to –13 mV.60 
It was found that the addition of PEG leads to a decrease in process yield, an increase in average diameter 
and zeta-potential of MPEM. However, the presence of PEG in MPSD resulted in a decrease of size and an increase 
of zeta-potential. Thus, CEF loading did not significantly affect size characteristics and process yield of MPs. The 
encapsulation efficiency of CEF was about 60% and 50% for MPEM and MPSD, respectively. 
The results of encapsulation efficiency correlate with those presented in the literature. Thus, encapsulation 
efficiency is found to depend on the nature of polymer and drug, amount of drug loaded, preparation/loading 
techniques. In the study of Kumar et al.
23
 lipid nanoparticles with CEF were obtained by the emulsion method and it 
was shown that encapsulation efficiency of CEF increased with increasing lecithin concentrations and at higher 
PVA values (EE about 71%–77%). While encapsulating CEF into lipospheres EE ranged from 29% to 60%.21 
Figure 1 shows the SEM images of CEF-loaded MPs. It was found, that the addition of PEG had important 
influence on the surface morphology and microstructure of MPs. Therefore, PCSD had a smooth surface, while the 
surface of the PPCSD was rough with the presence of small pores. Consequently, the addition of PEG as surfactant 
most likely led to a decrease in the amorphization of substances in the spray-drying process. A similar effect of the 
PEG used in spray drying was noted in the review of Paudel et al.
61
 Moreover, PPCEM were also characterized by a 
change in the structure upon the addition of PEG. However, in this case PEG was dissolved in the process of 
microparticles preparation, leading to the formation of deformed particles. According to Li et al.
62
 PEG influenced 
the formation of pores on the surface of microparticles, but only with the correct ratio PHBPEG. When the ratio of 
PEG was excessively high, the erosion and dissolving effect were so strong that it was impossible to integrate 
microparticles.
62
 On the whole, from the micrographs of Figure 1 it could be seen that the MPSD were spherical in 
shape and significantly larger in size, than the MPEM. 
 
Study of the CEF release from MPs in vitro 
CEF release profiles from MPEM and MPSD are presented in Figure 2. The mean amount of CEF released 
from PCSD and PPCSD was 51.3% and 39.1%, respectively, in the first 6 h and all the amount of drug from these 
formulations was released at 150 h (Figure 2(a)).  
Otherwise, CEF release from PCEM and PPCEM microparticles was seen retardant - the effect compared 
with PCSD and PPCSD (Figure 2(a)). In the first 6 h 9.4% and 2.6% of the CEF were released from the PPCEM and 
PCEM, respectively. About 15% of drug was released within 48 h for PPCEM, while 4% was released in the same 
period from PCEM. It is obvious that the drug release rate was increased when PEG was introduced into P3HB 
solution at emulsification technique. Likely, incorporation of PEG increased the release rate due to its high 
hydrophilicity and water solubility.
62-64
 As soluble filler, dissolution of PEG upon contact with a release medium 
would provide more channels for drug diffusion, inducing more drug molecules to be released. After 312 h, 34% 
and 10% of CEF were released from the PPCEM and PCEM microparticles, respectively. 
Earlier scientific literature reports that in the absence of biologic factors (enzymes, cells) the P3HB does 
not hydrolyze into carbon chains.
65
 This is due to the very high crystallinity and hydrophobic nature of polymer. 
Therefore, the rate of drug diffusion was substantially higher than that of polymer degradation, so the drug release 
profiles are more dependent on drug diffusion rather than on polymer degradation.  
The difference in the total release of CEF from MPEM and MPSD is most likely due to the fact that the 
drug molecules are differently encapsulated in the particles. MPEM had a relatively low total drug release, which 
could be explained by the hydrophobicity of P3HB and dense packing of polymer chains in the transformation 
process of microdroplets into microparticles, as a result, most of molecules of CEF being inside the particles. 
At the same time, it was found that the increase of CEF release rates from PCSD and PPCSD can be related 
to the fact that the part of CEF solidifies separately during co-spray drying polymers. The remaining part of CEF 
may most probably be located near the surface. Therefore, drug molecules close to the surface leave the matrix very 
easily. Most likely, the drug release from PCSD and PPCSD in the first 3–6h is associated with solubilization of free 
CEF. The next phase of CEF release (48–312 h) was dominated by the diffusion mechanisms associated with the 
drug release from the surface structures of microparticles.  
The data obtained from in vitro CEF release were fitted to different mathematical models, that is, Zero-
order, First-order, Higuchi, Hixson-Crowell, Korsmeyer-Pappas, to predict the kinetics and drug release mechanism.  
The release constant and regression coefficient (R2) values obtained from the mathematical models are 
shown in Table 2 and Figure 2(b, c). The data obtained shows that the formulations PCEM, PPCEM, and PPCSD 
follow Zero-order kinetics with R2 values of 0.922 and 0.925, 0.832, respectively. As shown, the formulations did 
not follow First-order kinetics. The data obtained for the formulations PCEM, PPCEM, and PPCSD best fit Higuchi 
model as indicated by the correlation coefficient, that is, 0.982, 0.963, and 0.894, respectively, indicating the CEF 
release from formulation followed Fickian diffusion. Low R2 values in all samples in Hixson–Crowell model 
indicate the absence of polymer erosion. The value of release exponent “n” obtained by applying Korsmeyer–Pappas 
equation for all formulations was <0.5 indicating CEF is released through Fickian diffusion from these formulations. 
Thus, the release profiles could be best explained by Zero-order, Higuchi and Korsmeyer-Peppas models. 
In this way, these results confirm that it is possible to prolong the drug release by varying the method of 
preparation and chemical composition of MPs. Microbiological evaluation In modern scientific literature, several 
approaches are used to evaluate the antibacterial efficacy of the developed drugs. Among the most common are the 
following: colony count method in bacterial broth suspensions
66
 and disc diffusion susceptibility test.
67
 In our work, 
we showed the possibility of successful loading of CEF in P3HB microparticles using various technologies. The 
antibacterial activity of CEF-loaded microparticles and empty particles against various bacterial strains including E. 
coli and S. aureus was investigated using the disk diffusion test with the zones of inhibition (ZOI) to be measured 
(Figures 3 and 4). The antibacterial activity was compared against susceptibility disk of CEF. 
The antibacterial efficiency of free CEF was higher against E. coli in comparison to S. aureus, which is 
consistent with these minimum inhibitory concentrations (MIC). It has been reported that the MIC of CEF against E. 
coli and S. aureus is 0.03–0.12 g/ml and 1–8 g/ml, respectively.68 Herewith, samples obtained by spray-drying 
showed higher antibacterial activity in comparison to disk (Figure 4). Presumably, this effect is associated with the 
prolonged effect of the loaded CEF. Based on the literature data, the encapsulation of biologically active substances 
can lead to improvement in their functional properties.
23,69
 The average diameter of ZOI caused by PCSD and 
PPCSD groups against E. coli were 26.5 ± 0.2 and 23.3 ± 0.1mm and was comparable to those against S. aureus 
(26.7 ± 0.2, 22.0 ± 0.3 mm). In contrast, the only sample obtained by the emulsification technique, PPCEM 
insignificantly suppressed growth of the more sensitive E. coli, while the remaining samples did not inhibit both E. 
coli and S. aureus (Figures 3 and 4). Probably this is due to insufficient concentration of released CEF (less than the 
MIC) from PCEM and PPCEM for the suppression of the growth of colonies after a short time of incubation. 
In the study of Attama et al.
21
 small inhibition zones were observed for liposphere batches formulated with 
10, 20, 30, and 40%w/w PEG 4000 and 1%w/w CEF probably because the concentration of drug contained in this 
batch was low to yield concentrations equal to or above the MIC to cause significant inhibition. 
It is also worth noting that there have been some case studies of antibiotic-loaded PH3B, while their 
applications for cephalosporins cannot be easily found. For instance, Vilos et al.
30
 developed ceftiofur-loaded PHBV 
microparticles, which showed a slight bacterial inhibition during the first 5 h and a delay in the onset of the bacterial 
exponential growth E. coli. As a control, the activity of empty P3HB microparticles and the physiological saline, 
used for suspending the microparticles, was checked. In both cases, no growth inhibition was observed in the 
analyzed cultures, which excludes the possibility of the influence of the chemical composition of the polymer and 
the medium used for suspending on the results of the efficacy of the encapsulated form of CEF. The results obtained 
correlate with the data presented in the paper by Hema et al.
70
 where the researchers confirmed the absence of 
antibacterial activity of empty films based on P(3HB), P(3HB-co-3HV) (6 mol%) and P (3HBco-4HB) (70 mol%) 
with respect to E. coli and S. aureus. 
 
CONCLUSION 
 
The outcome of this study is the successful development of CEF-loaded PHAs-based microparicles and 
their complex characterization. P3HB and P3HB-PEG microparticles were prepared by double emulsification 
technique and spray-drying. The encapsulation efficiency of CEF was about 60% and 50% for MPEM and MPSD, 
respectively. It was shown that the surfactants used in the emulsion method affect on the electrophoretic activity of 
the microparticles. Therefore, the zeta potential of MPEM was lower than that of MPSD by an average of three 
times. The addition of PEG to the P3HB solutions had important influence on the surface morphologies and 
microstructures of microparticles; however, the effect on drug release rate was clearly expressed only for MPEM. 
The total release of CEF from MPEM and MPSD had significant difference, which is most likely related to the 
localization of the drug molecules in the microparticles. Therefore, the CEF release of MPSD reached 100% after 
150 h, while for MPEM the total release of CEF did not exceed 34% for the entire observation period. The release 
profiles could be best explained by Zero-order, Higuchi, and Korsmeyer-Peppas models, as the plots showed high 
linearity. 
The bactericidal effect of MPEM and MPSD CEF-loaded was investigated in cultures of E. coli and S. 
aureus by disk diffusion test. MPSD with CEF showed higher antibacterial activity (ZOI over 22.0mm) in 
comparison to MPEM (ZOI not more than 5.1 mm). Thus, using various methods, the possibility of loading CEF in 
P3HB-carriers with satisfactory indicators of the encapsulation efficiency, drug release, and preservation of 
therapeutic activity in vitro is shown, which allows concluding that this class of polymers is promising for the 
development of long-acting dosage forms. 
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Table 1. Samples composition and characterization of the obtained microparticles 
Samples Process yield 
(%) 
Particle size (urn) Pdl Zeta -potential 
(mV) 
Encapsulation efficiency 
(%) 
Emulsification technique       
PEM      РЗНВ  725 0.74±18S2 0.187 ±0.063 -178 ±0.3 - 
РРEM     P3HB-PEG  39.0 155 ±0.05 0.167±0.037 -28.0 ±0.4 - 
РСEM     P3HB-CEF  71.4 089 ±0.02 0250 ±0.003 -223 ±0.6 66.0 
РРСEM   P3HB-PEG-CEF  268 155 ±0.01 0297 ±0.027 -25.0 ±0.1 60.5 
Spray-drying       
PSD         P3HB  332 651 ±0.47 0211 ±0.058 -95.7 ±0.6 - 
PPSD       P3HB-PEG  51.1 4.06 ±0.38 0318 ±0.192 -375 ±2.2 - 
PCsD      P3HB-CEF  85.7 421 ±0.70 0260 ±0.118 -48.0 ±1.4 50.6 
PPCSD     P3HB-PEG-CEF  345 384 ±0.27 0224-0.058 -38.7 ±1.2 47.0 
 
Table 2. Release parameters of CEF from microparticles in PBS in vitro. 
 Zero-order First- order Higuchi Hixson-Qowell Korsmeyer-Pappas 
Samples R2 K0h
-1 R
2 K1h
-1 R
2 KHh
-0.5 R
2 KHC
(h-1/3) n R2 
PCEM 
PPCEM 
PCSD 
PPCSD 
0.922  
0.925  
0.699  
0.832 
0.027 
0.099 
0.295 
0.302 
0.671 
0.605 
0.463 
0.565 
0.006 
0.006 
0.003 
0.004 
0.982  
0.963  
0.766 
0.894 
0.539 
1.900 
4.377 
5.012 
0.766 
0.705 
0.494 
0.621 
0.003  
0.005  
0.004  
0.005 
0.017 
0.062  
0.161 
0.173 
0.920 
0.935 
0.936 
0.967 
 
 
 
 
Figure 1. SEM images and size distribution of microparticles with CEF: (a) microparticles of poly-3-
hydroxybutyrate prepared by emulsification technique; (b) microparticles of poly-3-hydroxybutyrate/PEG prepared 
by emulsification technique; (c) microparticles of poly-3-hydroxybutyrate prepared by spray-drying; (d) 
microparticles of poly-3-hydroxybutyrate/PEG prepared by spray-drying. Bar represents 10 m. 
 
 
Figure 2. Release assays (a), kinetic profiles of CEF loaded in microparticles of () PCEM, () PPCEM, () 
PCSD, (●) PPCSD; (b) Mechanism of CEF release by Zero-order model; (c) Mechanism of CEF release by Higuchi 
model. 
 
 
 
Figure 3. Images of antibacterial activity of microparticles against E. coli and S. aureus. 
 
 
 
Figure 4. Antibacterial activity of microparticles against E. coli and S. aureus. Diameter of inhibition zones in mm. 
